Prevalence of hepatopathy in type 1 diabetic children by Abdulrahman A Al-Hussaini et al.
Al-Hussaini et al. BMC Pediatrics 2012, 12:160
http://www.biomedcentral.com/1471-2431/12/160RESEARCH ARTICLE Open AccessPrevalence of hepatopathy in type 1 diabetic
children
Abdulrahman A Al-Hussaini1*, Nimer M Sulaiman2, Musa D AlZahrani2, Ahmed S Alenizi2 and Mannan Khan3Abstract
Background: The Prevalence of liver disease among diabetics has been estimated to be between 17% and 100%.
Most of these data were obtained from adult studies. The aim of our study was to screen for liver disease among
type 1 diabetic children.
Methods: Children with type 1 diabetes following in clinic have been examined for existence of liver disease, from
November 2008 to November 2009. All were subjected to the following: History, physical examination, liver function
tests, fasting lipid profile, HbA1C, and ultrasound of the liver. A hyperechogenic liver and/or hepatomegaly on
ultrasound were attributed most likely to excess glycogen or fat in the liver, after negative extensive work-up to
rule out other underlying liver disease.
Results: 106 children with type 1 diabetes were studied: age ranged between 8 months to 15.5 years, sixty two
patients were females. Twenty two patients (21%) were identified to have abnormal findings on ultrasound of the
liver: 10 patients had hepatomegaly and 12 had hyperechogenic liver. The group with hyperechogenic liver had
poorer glycemic control than patients with normal liver (Mean HbA1c 12.14% Vs 10.7%; P value = 0.09).
Hyperechogenic liver resolved in 60% at 6 months follow-up upon achieving better glycemic control.
Conclusions: Hyperechogenic liver and/or hepatomegaly are not uncommon in children with type 1 diabetes and
tend to be more prevalent among children with poor glycemic control. Type 1 diabetes related hepatopathy is
reversible by optimizing glycemic control. Because of its safety, and reliability, ultrasound can be used to screen for
hepatopathy in type 1 diabetic child.
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Type 1 diabetes is a disorder of glucose metabolism that
results from insulin deficiency secondary to autoimmune
destruction of insulin-secreting β-cells. The prevalence
of liver disease among diabetics is estimated to be be-
tween 17% and 100% [1-5]; fatty liver and hepatic glyco-
genosis being the predominant pathologies. Most of
these data were obtained from studies of obese adults
with non-insulin dependent diabetes. Since obesity may
also be a major cause of hepatic abnormalities [1,4], it is
difficult to identify diabetes as a specific factor for liver
disease in obese diabetic adults. In a histopathological-
based study in 91 adults with diabetes, fatty liver was* Correspondence: aa_alhussaini@yahoo.com
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distribution, and reproduction in any mediumdiagnosed in 63% of patients with type 2 diabetes com-
pared with 17% of patients with type 1 diabetes [2]. Be-
cause the frequency of obesity in adults with type 2
diabetes was higher than in patients with type 1 diabetes,
it is not surprising that the incidence of fatty liver is dif-
ferent as well.
The pediatric literature about type 1 diabetes– related
liver disease is largely limited to small case series or case
reports for children presenting with symptomatic hepatic
dysfunction during metabolic decompensation and ketosis
[6-11]; hepatic glycogenosis being the most frequent eti-
ology and much less frequent cases of hepatic steatosis.
Screening metabolically stable children with type 1 dia-
betes for liver disease had been the subject of a single re-
cent study [12] that showed a prevalence of abnormal
hepatic ultrasound (hepatomegaly and/or hyperechogeni-
city) in 4.5% of screened children. However, ultrasoundtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 (a) Marked hyperechogenicity of the liver resulting
into large discrepancy between hepatic and renal echoes. (b)
Normal echogenicity of the liver after proper glycemic control.
Al-Hussaini et al. BMC Pediatrics 2012, 12:160 Page 2 of 8
http://www.biomedcentral.com/1471-2431/12/160criteria used to define echogenicity and size of the liver
were ill-defined. The aim of our cross-sectional and pro-
spective study was to highlight the prevalence of diabetic
hepatopathy in children with type 1 diabetes using well-
defined ultrasound parameters to define echogenicity and
size of the liver, in addition to clinical assessment and la-
boratory tests. Another objective was to evaluate the effect
of implementation of measures to achieve glycemic con-
trol on diabetic hepatopathy.
Methods
Children with type 1 diabetes in follow up in diabetes
clinic in our tertiary care center were consecutively en-
rolled into the study. They presented initially and
received therapy in our hospital and had not been trea-
ted for diabetes elsewhere. We excluded children with
liver abnormality unrelated to diabetes or due to
associated diseases. Children and their parents who
have attended the diabetic clinic over the period from
November 2008 to November 2009 and have accepted
entry into the study were interviewed by the researchers
and given an idea about the purpose of the study, and an
informed consent form was signed. Children and their
parents were asked to fill up a questionnaire to collect
data about: demographics, duration of diabetes, insulin
dosage, gastrointestinal or hepatic symptoms, and asso-
ciated autoimmune diseases. Heights and weights were
measured by clinic nurses using electronic scale and plot-
ted on a sex and age appropriate growth chart, and body
mass index (BMI) calculated. BMI ≥95th centile for age
and sex defined obesity and BMI ≥ 85th% - 95th% defined
overweight. Hepatomegaly was assessed clinically by
measuring the distance between the upper and lower bor-
ders of the liver at mid-clavicular line using a tape
measure.
Blood was collected for: Liver enzymes (Alanine ami-
notransferase [ALT], aspartate aminotransferase [AST],
alkaline phosphatase, gamma glutamyl transferase), total
bilirubin, total protein and albumin, glycosylated
hemoglobin (HbA1C), and fasting lipid profile. Hyper-
cholesterolemia was defined as serum cholesterol > 5.15
mmol/L and hypertriglyceridemia was defined as serum
triglyceride > 2.2 mmol/L. In our laboratory, normal
ALT and AST are 30–65 IU/L and 15–37 IU/L, respect-
ively. HbA1C > 10% defined poor glycemic control.
Liver ultrasound was performed by a single senior
pediatric radiologist to evaluate for presence of increased
echogenicity or hepatomegaly. Ultrasound was per-
formed using 3.5 –7.5 MHz curvilinear transducer on
Aloka prosound SSD 4000 without any preparation.
Radiologist was blind to clinical data of patient. Patients
were placed on supine, right anterior oblique position to
demonstrate the porta hepatis. Longitudinal images were
obtained in the mid clavicular line. The length of theliver was measured from uppermost portion of the dome
of diaphragm to the inferior tip. Uniform pattern of
medium strength echoes from liver was considered as
normal whereas increased strength of echoes resulting
into marked liver-kidney echogenic discrepancy and
poor definition of hepatic veins, portal vein, and crus of
diaphragm was considered as increased echogenicity of
liver [Figure 1(a)]. Length of liver above standard devi-
ation (SD) of mean for normal liver size in children [13]
was reported as enlarged liver. A liver size up to 2 cm
above SD of mean for age and sex was considered as
Mild Hepatomegaly, 2 to 4 cm above SD of mean defined
moderate hepatomegaly, and liver size more than 4 cm
above SD of mean defined severe hepatomegaly.
Presence of hepatomegaly and/or hyperechogenic liver
on ultrasound abdomen was an indication for further la-
boratory work up to investigate other possible liver
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face antigen, Anti-HCV antibody, serum copper and cer-
uloplasmin, serum immunoglobulins, anti-nuclear
antibody quantitation (by Immunoflourescence assay
using Diasorin kit), smooth muscle antibody qualitative
test (by Enzyme linked immunoassay using Diasorin
kits), and Anti-Liver Kidney microsomal antibody (by
Enzyme linked immunoassay using Diasorin kits), serum
alpha 1 anti-trypsin, serum ferritin, serum iron, transfer-
ring saturation, and total iron binding capacity, urine for
organic acids and plasma for amino acids, to evaluate
for possibility of viral hepatitis B and C, wilson's disease,
autoimmune liver disease, alpha 1 anti-trypsin deficiency
disease, hemochromatosis, and metabolic disorder, re-
spectively. We considered the finding of hyperechogenic
liver and/or hepatomegaly on ultrasound and negative
screening work up for underlying liver disease as con-
sistent with a likely diagnosis of hepatic glycogenosis or
less likely fatty liver. Liver biopsy was indicated if there
is hepatomegaly and/or hyperechogenic liver on ultra-
sound and elevation of ALT and AST > 1.2 times of nor-
mal values. A liver biopsy was deemed unnecessary if
there is hepatomegaly and/or hyperechogenic liver on
ultrasound but normal liver function tests.
During the same study period, all 106 children with
type 1 diabetes underwent screening for celiac disease
using IgA tissue transglutaminase (IgA-TTG) [ELISA
assay using Inova kit], endomyseal antibodies (EMA)
[IFA assay using Inova kit], and total IgA level (unpub-
lished data). Patients with positive IgA-TTG (> 20 units
IU/L) and/or EMA underwent upper endoscopy and in-
testinal biopsies. Histopathology of the intestinal biop-
sies was graded according to Marsh classification [14].
Children with hyperechogenic liver and/or hepatomeg-
aly and their parents were interviewed by an endocrin-
ologist and dietitian and received counseling on
importance of the liver finding and dietary intake was
reviewed. In attempt to achieve glycemic control, par-
ents and patient were encouraged to adhere to diabetic
diet and, when appropriate, insulin dosage has been
adjusted. At 3 months follow up, dietary compliance was
reviewed by a dietitian. At 6 months follow up, blood
was collected for HbA1C and ultrasound of liver was
repeated. Radiologist was blind to the clinical data at
repeated ultrasound.
The study has been approved by institutional review
board and the procedures are in accordance with the
Declaration of Helsinki.
Statistical analysis
The data were analyzed using SPSS pc+ version 11.0
statistical software. Descriptive statistics (mean, standard
deviation and proportions) were used to summarize the
study variables. Student’s t-test for independent sampleswas used to compare the mean values of continuous
study variables. The 95% confidence intervals for differ-
ence of mean were used. A p-value of less than 0.05 was
used as a statistically significant.
Results
Over the one-year study period, 106 children with type 1
diabetes were investigated: age ranged between 8 months
and 15.5 years (Mean 8.5 years and standard deviation
[SD] ± 2.8 years), sixty two were females and 44 males.
Mean Age at diagnosis of type 1 diabetes was 6.3 ± 2.9
years (range 0.85 – 11 years). Mean time of duration of
type 1 diabetes is 2.2 ± 2.1 years (range 0 – 8 years).
Seven patients were newly diagnosed. Mean HbA1c was
10.7 ± 2.4%, and 61.3% of the patients had HbA1c more
than 10%. Mean serum cholesterol was 4.16 ± 0.75
mmol/L (Normal 3.65 – 5.15 mmol/L) and mean serum
triglyceride 1.02 ± 1.3 mmol/L (Normal 0 – 1.7 mmol/L).
Only one child had hypercholesterolemia (serum choles-
terol of 6.2 mmol/L) and another one had hypertriglyceri-
demia (serum triglyceride 3.5 mmol/L). None of the
patients had elevated liver enzymes.
Ultrasound of the liver identified 2 groups of patients
with abnormal liver imaging: a group of 11 children with
hepatomegaly and normal echogenicity, One of them
has β-thalasemia major so was excluded from the study,
and another group of 12 children with hyperechogenic
liver. None of the 22 patients had a history of hepato-
toxic drug or family history of liver disease, and none
had stigmata of chronic liver disease. The screening
workup for possibility of underlying liver disease was
negative. None of 106 children had gall bladder stones.
Table 1 shows the group of children with type 1 dia-
betes and ultrasound-diagnosed hepatomegaly. Clinical
hepatomegaly was identified in 6 of the 10 patients; 3
cases of mild hepatomegaly and one case of moderate
hepatomegaly on ultrasound were missed by clinical as-
sessment. One patient was obese and none of the
remaining was overweight. None of the group had short
stature. None of the patients had elevated liver enzymes
or hyperlipidemia. Mean HbA1c for this group was
9.4%. Comparison of the group of children with type 1
diabetes and hepatomegaly to patients with type 1 dia-
betes and no hepatomegaly shows no statistically signifi-
cant differences as the age, duration of type 1 diabetes,
HbA1c, insulin dose, and lipid profile are concerned.
Table 2 shows the group of patients with hyperecho-
genic liver on ultrasound. None of the group had elevated
liver enzymes. Two patients were obese and none of the
remaining was overweight. None of the group had short
stature. Two patients had hyperlipidemia. Patient 2 had
serum cholesterol of 6 mmol/L and patient 12 had serum
triglyceride of 3.5 mmol/L. Comparison of the group of
children with type 1 diabetes and hyperechogenic liver to
Table 1 Children with type 1 diabetes and hepatomegaly
Patient Age (year) Sex Duration of diabetes (year) BMI (Kg/m2) U/S Liver size (cm) (severity)
1 15 M 4 22.7 15 (mild)
2 3.5 F 0.5 18.5 10.4 (Mild)
3} 13 M 4 18.5 15.8 (Moderate)
4 8 M 1.5 16.57 12.6 (Mild)
5 4.5 M 3 16.6 10.5 (Mild)
6 9 F 0.4 13.7 16.7 (Severe)
7 11 M 3 17.5 12.2 (Mild)
8 4 M 3 15.7 10.2 (Mild)
9 4.5 M 1.5 16 11.8 (Moderate)
10 15.5 M 5.5 17.1 13.7 (Mild)
BMI: Body mass index, }: Obese patient, HbA1c: Glycosylated hemoglobin, U/S: Ultrasound, F: female, M: male.
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(Table 3) shows no statistically significant differences as
the age, duration of diabetes, HbA1c, insulin dose, and
lipid profile are concerned. Four patients (Patients 3, 5, 9,
and 10) with hyperechogenic liver and type 1 diabetes (33%)
were diagnosed to have celiac disease compared to eight
patients with celiac disease in the non-hyperechogenic liver
group (8.5%) (P value = 0.04).
Table 4 shows data on ultrasound of the liver at 6
months follow up post- implementation of measures to
achieve glycemic control in patients of both hyperecho-
genic liver and hepatomegaly groups. Six of 10 in the
hepatomegaly group (60%) and 7 of 12 in hyperecho-
genic liver group (58%) had normal liver on ultrasound
after achievement of better glycemic control [Figure 1 (b)].
Children with persistent hepatomegaly were non-adherent
to diabetic diet and HbA1C worsened despite increasing
the dose of insulin. All children who achieved normal liver
size, except patient 5, achieved better glycemic control byTable 2 Children with type 1 diabetes and hyperechogenic liv
Patient Age (Year) Sex Duration of
1 7 M 3
2* 10.5 M 4.5
3{ 12 F 3
4 9 F 2
5{ 9.5 F 4.5
6 11.5 F 4.5
7} 8 M 7
8 3.5 M 0.1
9{ 11 F 0.3
10{ 13 F 6
11 11 M 0.3
12*} 10 M 0.5
BMI: Body mass index, HbA1c: Glycosylated hemoglobin, U/S: Ultrasound, *: patient
M: male.good adherence to diabetic diet that led to subsequent re-
duction of insulin dose. Glycemic control in children with
resolved hyperechogenic liver was achieved by good adher-
ence to diabetic diet and increasing insulin dose. Five chil-
dren had persisted hyperechogenic liver: patients 4, 6, and
12 were non-adherent to diabetic diet and patients 9 and
10, although their glycemic control improved, but they
were not compliant on gluten free diet and had persistently
high IgA TTG.
Discussion
The major finding of our study is the increased preva-
lence of of abnormal liver findings on ultrasound in chil-
dren with type 1 diabetes (21%). The negative screening
work up for underlying hepatic pathology (like viral
hepatitis, autoimmune hepatitis, metabolic disease,
Wilson’s disease, alpha 1 anti-trypsin deficiency, and
hemochromatosis) makes the ultrasound finding of
hyperechogenic liver and/or hepatomegaly in a childer













has hyperlipidemia, }: Obese patient, {: Patient with celiac disease, F: female,
Table 3 Comparison of Mean values of study variables in relation to presence or absence of hyperechogenic liver in
type 1 diabetes children
Study variables (Mean) Hyperechogenic liver Yes (12) No (84) P - value
Age (year) 9.7 8.3 0.11
Duration of diabetes (Year) 3 2 0.18
Height (Z score) 0.20 0.068 0.35
BMI (Z score) 0.66 - 0.12 0.14
HbA1c % 12.14 10.7 0.09
Insulin dose(Units/kg/day) 0.68 0.74 0.24
Triglyceride (mmol/L) 1.1 0.98 0.76
Cholesterol (mmol/L) 4.3 4.1 0.41
BMI: Body mass index, HbA1c: Glycosylated hemoglobin.
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in the liver.
In type 1 diabetes, the insulin deficiency leads to low
hepatic glucokinase levels resulting in decreased glucose
uptake, and together with elevated glucagon levels
stimulate glycogenolysis and gluconeogenesis [1]. There-
fore, the low or absent insulin levels results in enhancedTable 4 Ultrasound of liver at 6 months follow up post-imple
patients with hyperechogenic liver and/or hepatomegaly
Hepatomegaly group At baseline




















9{ } 0.46 14.1
10{ } 0.75 13
11 0.72 13
12* 0.46 8.2
{: patient with celiac disease; *: Non-adherent to diabetic diet; }: Non-adherent to grate of glucose output by the liver and diminished hep-
atic glucose uptake. Treatment with insulin reverses
these changes and normalizes uptake of glucose by hepa-
tocytes and increases hepatic glycogen content. It has
been shown in insulin-deficient rats given a single dose
of insulin that glycogenosis persist for a substantial
period after blood glucose returned to their initialmentation of measures to achieve glycemic control in
At 6 months follow up
Insulin (U/kg/d) HbA1C% U/S liver
0.70 8.7 Normal
0.75 11 Mild hepatomegaly
0.7 7.4 Normal
0.5 8 Mild hepatomegaly
0.75 7.2 Normal
0.8 7.5 Normal
0.7 8.8 Mild hepatomegaly






0.75 12.4 hyperechogenic liver
0.85 7.4 Normal
0.9 13 hyperechogenic liver
0.75 9 Normal
0.70 8.2 Normal
0.75 10.5 hyperechogenic liver
0.90 9.8 hyperechogenic liver
0.80 8.8 Normal
0.65 10.5 hyperechogenic liver
luten free diet.
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mulation of hepatic glycogen is promoted by high cyto-
plasmic glucose concentration in presence of insulin.
The Japanese literature reports 20 cases of diabetes
mellitus-associated hepatomegaly and mild hepatic dys-
function attributed (especially in cases of type 1 dia-
betes) to chronic overinsulinization [16]. Hepatic
glycogenosis has been reported to occur at first presen-
tation of type 1 diabetes after receiving supraphysiologi-
cal doses of insulin [11]. Therefore, longstanding
hyperglycemia and overinsulinization are considered
metabolic pre-requisites for hepatic glycogen storage.
Also it has been suggested that patients who take excess
insulin and treat the subsequent hypoglycemic episodes
by administering glucose also promote hepatic glycogen
accumulation. Thus a vicious cycle of hyperglycemia and
intermittent insulin administration results in glycogeno-
sis. The group of our patients with hepatomegaly had
more significant number of hypoglycemic episodes and
higher mean insulin dose compared to the group with
no hepatomegaly. This might explain their liability to de-
velop hepatic glycogenosis.
In type 1 diabetes, insulin deficiency stimulates lipolysis
and increases the mobilization of peripheral free fatty
acids, and their increased hepatic uptake enhances very
low density lipoprotein and triglycerides synthesis [1]. The
coexistent elevated glucagon levels inhibit hepatic trigly-
cerides output. Therefore, hepatic steatosis in type 1 dia-
betes is thought to be a combination of an increased
hepatic production of triglyceride and decreased removal.
The group of our patients with hyperechogenic liver had
poorer glycemic control, as indicated by their elevated
mean HbA1C (12.14%), as compared with type 1 diabetes
patients without hyperechogenic liver. This difference
didn't reach statistical significance, which may be the re-
sult of relatively small sample size. Adequate insulin ther-
apy can inhibit lipolysis and reverse the process. In
contrast, in type 2 diabetes with high frequency of concur-
rent obesity, insulin insensitivity rather than the degree of
glucose intolerance is predictive of the occurrence of hep-
atic steatosis [1]. As a result, weight loss has been shown to
decrease the elevated hepatic free fatty acids concentration.
The pediatric literature about type 1 diabetes related
liver disease is scant and mostly limited to small case
series or case reports for children presenting with symp-
tomatic hepatic dysfunction during time of metabolic
decompensation and ketosis [6-11]; hepatic glycogenosis
being the most frequent etiology and much less frequent
cases of hepatic steatosis. Our study uncovers that type
1 diabetes related hepatopathy is not uncommon. Here,
we report a prevalence of 21% (22 of 105) which is lower
than the prevalence of fatty liver of 44% reported in
adults with type 1 diabetes [17]. In the latter study, BMI
was significantly higher in patients with type 1 diabetesand fatty liver as compared to those with type 1 diabetes
without fatty liver, which suggests that obesity might be
the major contributing factor for development of fatty
liver in adults with type 1 diabetes. Unlike in adults with
type 1 or type 2 diabetes and fatty liver, obesity was not
a major factor in our patients; only 2 of 22 patients (9%)
with type 1 diabetes related hepatopathy in our study
were obese. This observation reinforces the thought that
the pathogenesis for development of hepatopathy in type
1 diabetes and type 2 diabetes is different and subse-
quently the target of therapy will be different. Whereas
adequate insulin dosage and adherence to diabetic diet
are required to reverse hepatopathy in type 1 diabetes,
weight loss helps improvement of insulin insensitivity in
type 2 diabetes and ultimately inhibits lipolysis.
In a large study of 692 Egyptian children with type 1 dia-
betes, El-Karaksy et al. [12] reported a prevalence of 4.5%
of abnormal liver findings (hyperechogenicity and hepato-
megaly) on ultrasound as compared to 21% in our study.
The higher frequency of liver abnormality on ultrasound in
our study could be attributed to the poorer glycemic con-
trol of our patients; 61.3% have HbA1c > 10% as compared
to 24% in El-Karaksy's study. Another explanation for vari-
ation in prevalence of abnormal liver findings between the
two studies could be related to the methodology used. In
El-Karaksy's study, ultrasound criteria used to define echo-
genicity of the liver were not mentioned, definition of hep-
atomegaly was not stated, and radiologist was not blind to
clinical data. In our study, we have considered several reli-
able ultrasound parameters to define echogenicity of the
liver and we defined hepatomegaly in reference to normal
liver size in age and sex matched children [13]. In addition,
the ultrasound was performed by a single radiologist blind
to clinical data to minimize bias. In a recent meta-analysis
on the diagnostic accuracy and reliability of ultrasound for
the detection of fatty liver, the use of different ultrasound
criteria to define echogenicity of liver was among the most
important causes for the variation of estimates of fatty liver
between studies [18]. In the same met-analysis, the accur-
acy of ultrasonographic parameters of fatty liver definition
were evaluated individually and the sensitivities of liver to
kidney contrast and vessel wall brightness, two criteria we
used to evaluate for fatty liver in our study, were 98% and
81% respectively, with specificity between 93% to 95% for
both parameters.
Data from our study indicate that type 1 diabetes related
hepatopathy can be silent unless screened for by ultra-
sound. Majority of the cases reported in the pediatric lit-
erature were for children presenting in metabolically
decompensated conditions and in diabetic ketoacidosis
states; these cases manifested hepatic symptoms and evi-
dence of liver dysfunction. The liver enlargement in these
cases may be so fast that it causes stretching of the liver
capsule and abdominal pain. The design of our study to
Al-Hussaini et al. BMC Pediatrics 2012, 12:160 Page 7 of 8
http://www.biomedcentral.com/1471-2431/12/160screen metabolically stable children may have contributed
to the asymptomatic nature of hepatopathy in our cohort.
Our data suggest that the prognosis of type 1 diabetes
related hepatopathy is excellent and the process is revers-
ible with optimal control of blood glucose. Diabetic hepatic
glycogenosis is a benign condition that tends to resolve in
response to establishment of glycemic control [6,19] and no
report exists of progression to fibrosis. However simple
steatosis may incite an inflammatory response leading to
steatohepatitis. The natural history of steatohepatitis is
still being defined, however progression to fibrosis oc-
curred in 48% of patients [20] and cirrhosis had been
reported in 10 – 15% [20,21]. The increased prevalence of
fatty liver among patients with type 1 diabetes has import-
ant implications on their clinical care. Detection of hepatic
steatosis at an early stage in children with type 1 diabetes
might offer them the advantage of reversibility by proper
glycemic control. Persistence of hyperechogenic liver in
patient 9 and 10 despite better glycemic control could be
due to celiac disease, a recognized cause of fatty liver [22].
Ultrasound of liver is a valuable non-invasive tool to diag-
nose liver disease in children with type 1 diabetes. All of
the 22 children with abnormal liver findings on ultrasound
were asymptomatic, and demonstrated normal liver
enzymes; therefore the dependence on clinical data and
liver function tests to detect liver disease could have missed
those cases. Ultrasound has a sensitivity of 80% and a speci-
ficity of almost 100% for steatosis [18,23], especially for the
detection of moderate to severe fatty infiltration. The sensi-
tivity and specificity of ultrasound for detection of fatty liver
is similar to that of imaging techniques (computed tomog-
raphy or magnetic resonance imaging) [18]. Therefore, we
think that ultrasound of liver is indicated to screen for
hepatopathy in diabetic children particularly those with per-
sistent poor glycemic control. However, histopathological
demonstration of glycogen or fat accumulation in hepato-
cytes remains the gold standard to diagnose glycogenosis or
fatty liver and to differentiate simple steatosis from steato-
hepatitis. The ultrasound finding of hepatomegaly is non-
specific and, in a child with type 1 diabetes, could be due to
increased accumulation of fat or glycogen in hepatocytes.
Our inability to confirm the ultrasound finding of fatty liver
or hepatic glycogenosis on histopathological ground and
lack of control group are limitations in our study. None of
our patients showed an elevation of liver transaminases; a
criterion we have set in our study protocol to justify doing
liver biopsy.
Conclusion
Type 1 diabetes related hepatopathy is not uncommon
and tends to be more prevalent among children with
poor glycemic control. Type 1 diabetes related hepatopa-
thy is reversible by optimizing glycemic control. Because
of its low cost, safety, reliability, and accessibility,ultrasound can be used to screen for hepatopathy in
children with type 1 diabetes.
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